Artemis Medicare Serv Share Price

Artemis Medicare Services Limited (Artemis Medicare) is a leading multi-specialty tertiary care hospital chain in India, primarily engaged in the management and operation of advanced healthcare facilities. The company provides a comprehensive range of medical and surgical interventions, inpatient and outpatient services across specialties such as oncology, cardiology, neurology, orthopaedics, nephrology, gastroenterology, and critical care. Artemis Medicare operates a 541-bed super-specialty hospital in Gurugram along with Artemis Lite, Daffodils, and Artemis Cardiac Care centres across the Delhi NCR region. The Artemis Medicare share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Artemis Medicare stock price often mirrors shifts in healthcare demand patterns, medical tourism inflows, and investor views on the hospital sector’s growth prospects. Factors such as the pace of bed capacity expansion, competitive intensity from other hospital chains, regulatory changes, and government policies on health insurance influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Artemis Medicare price movements.

Artemis Medicare live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Artemis Medicare live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Artemis Medicare share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Artemis Medicare Services Limited Company Fundamentals

a. Company Background

Artemis Medicare Services Limited was incorporated in 2004. The company’s registered office is located in Gurugram, Haryana. The company was incorporated on May 18, 2004 and is promoted by the Apollo Tyres Group. It commenced commercial operation by setting up Artemis Hospital (formerly Artemis Health Institute) at Gurugram on July 16, 2007. Artemis Medicare Services Limited is the holding company of Artemis Cardiac Care Private Limited and a subsidiary of Constructive Finance Private Limited. The company’s primary activity involves the management and operation of multi-specialty hospitals in India. It initially focused on building a strong foothold in the Delhi NCR healthcare market before gradually expanding its footprint through the Artemis Lite, Daffodils, and Artemis Cardiac Care brands. The company provides a comprehensive range of advanced medical and surgical services across specialties such as cardiology, oncology, orthopedics, neurology, nephrology, gastroenterology, and critical care. Over the years, Artemis Medicare has significantly expanded its bed capacity and service portfolio. It operates in a competitive environment, with pricing and service delivery governed by market forces and regulatory frameworks. The company has consistently focused on enhancing its clinical capabilities to meet the growing demand for quality healthcare in India.

b. Product Lines

• Multi-specialty tertiary care hospital services at 541-bed flagship facility in Gurugram, providing advanced medical and surgical interventions across 30+ specialties

• Artemis Lite centres offering secondary care and outpatient services in neighbourhood locations

• Daffodils brand hospitals focusing on women and child healthcare services

• Artemis Cardiac Care centres in joint venture with Philips, providing specialised cardiac diagnostic and treatment services

• Inpatient services including emergency and trauma care, intensive care units, and post-operative care

• Outpatient services including consultations, diagnostic tests, preventive health check-ups, and day-care procedures

• Oncology services including chemotherapy, radiation therapy, and surgical oncology

• Cardiology and cardiac surgery services including interventional cardiology and bypass surgeries

• Neurosciences including neurology, neurosurgery, and stroke management

• Orthopaedics including joint replacement, spine surgery, and sports medicine

• Nephrology including dialysis and kidney transplantation

• Gastroenterology including endoscopic procedures and liver care

• Bariatric and minimally invasive surgery services

• Home care services, medical interpreter services, and smoking cessation programs

• International patient services including medical tourism facilitation

c. Company Revenue Model

• Primary revenue from healthcare services through the operation of multi-specialty hospitals, with revenue diversified across specialties: Oncology (19%), Neurosciences (15%), and Orthopaedics (14%) serving as the primary contributors

• Volume-driven revenue based on number of inpatient admissions, outpatient consultations, surgical procedures, and diagnostic tests

• Pricing determined by procedure complexity, length of stay, specialty mix, and insurance reimbursement rates

• Revenue from inpatient services including room rent, doctor fees, surgical charges, and medication

• Revenue from outpatient services including consultation fees, diagnostic tests, and pharmacy sales

• Revenue from Artemis Cardiac Care centres operating under joint venture with Philips

• Revenue from international patient services and medical tourism

• Expanding bed capacity and service portfolio contributing to new revenue streams through increased patient volumes

• Focus on increasing share of high-margin specialty procedures including oncology, neurosciences, and cardiac care to drive better profitability

• Revenue from both cash-paying patients and insurance reimbursements

• Seasonal variations in elective procedures affecting revenue patterns throughout the year

• Government policies on health insurance and price regulation influencing revenue stability

d. Geographic Presence

• Headquartered in Gurugram, Haryana with registered office at Artemis Hospitals, Sector 51, Gurugram – 122001

• Flagship facility: 541-bed super-specialty tertiary care hospital in Gurugram, spread across 9 acres, with NABH and JCI accreditations

• Artemis Lite centres: Multiple locations across Gurugram and Delhi NCR providing secondary care and outpatient services

• Daffodils hospitals: Centres focusing on women and child healthcare

• Artemis Cardiac Care centres: Seven centres operating under joint venture with Philips

• Recent expansion: Announced agreement to operate 650+ bed Vimhans Hospital in Delhi

• Strong presence across Delhi NCR region with a total of 713 beds predominantly in the region

• Focus on expanding into new geographical areas through organic growth and operational agreements

• International patient services catering to medical tourists from across the globe

e. Key Milestones

• 2004: Incorporated as Artemis Medicare Services Limited on May 18, 2004

• 2007: Commenced commercial operation by setting up Artemis Hospital (formerly Artemis Health Institute) at Gurugram on July 16, 2007

• 2024: Raised Rs 330 crore from IFC to increase bed capacity and introduce advanced specialty services

• 2025: Ended FY24-25 with gross revenues of Rs 922 crore and a net profit of Rs 49 crore

• 2026: Announced agreement to operate 650+ bed Vimhans Hospital in Delhi, significantly expanding footprint

f. Industry Perspective

Artemis Medicare Services Limited operates in the hospital and healthcare services industry, which is part of India’s broader healthcare sector. Globally, the healthcare market continues to expand with the Asia-Pacific region being the fastest-growing market. In India, the hospital sector is poised for substantial growth. According to CareEdge Ratings, the hospital industry in India is projected to grow at a CAGR of 11-12% over the next 3-5 years, driven by a structural deficit of nearly two million beds and rising insurance penetration. According to CRISIL Ratings, private hospitals are set to report 14-15% revenue growth in fiscal 2027, marking the fifth consecutive year of double-digit growth, supported by high bed occupancy and rising average revenue per occupied bed (ARPOB). The India hospital market was valued at USD 108.57 billion in 2024 and is expected to reach USD 197.31 billion by 2030, growing at a CAGR of 10.64%. According to ICRA, the hospital sector is expected to maintain high occupancy rates of 62-64 per cent in FY2026, following a strong 63.5 per cent occupancy in FY2025. India’s medical tourism market, valued at USD 7.7 billion in 2024, is projected to double to USD 16 billion by 2030. The single-specialty healthcare market is projected to triple to over $12 billion by 2030, growing at a 22% CAGR. Demand is driven by rising health insurance penetration, increasing prevalence of chronic diseases, growing medical tourism, and government initiatives like Ayushman Bharat. Key challenges include intense competition, regulatory price controls, talent retention, and high capital expenditure requirements.

Artemis Medicare Services Limited Stock Market Presence: Listings & Index Representation

Artemis Medicare is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol ARTEMISMED and on the Bombay Stock Exchange (BSE) with the scrip code 542919. Its listing on both exchanges ensures that the Artemis Medicare price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company forms part of several benchmark indices that represent broad market segments. Artemis Medicare is included in BSE 1000, BSE AllCap, BSE Consumer Discretionary, BSE MidSmallCap, BSE NEXT 500, and BSE SmallCap indices. Being represented in multiple indices enhances the visibility and liquidity of the Artemis Medicare price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s healthcare landscape. The inclusion of Artemis Medicare in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the Artemis Medicare price to corporate and industry developments. The company’s ISIN code is INE025R01021 and face value is ₹1 per share.

Artemis Medicare Services Limited Stock Performance and Share Price History

The Artemis Medicare price has exhibited significant volatility over the past decade, shaped by the company’s operations in India’s healthcare sector and broader industry cycles. The Artemis Medicare price recorded a total return of approximately -19.96% over the last 1 year, underperforming the BSE Healthcare index’s returns over the same period, reflecting near-term headwinds including valuation concerns and competitive pressures. The Artemis Medicare share price delivered a 5-year total return that has been positive, demonstrating moderate long-term wealth creation. The Artemis Medicare share price reached a 52-week high of ₹306.00 and a 52-week low of ₹203.35, indicating a wide trading range and substantial price fluctuations. The Artemis Medicare share price recorded a strong rally in 2023, while the subsequent period has seen the Artemis Medicare price moderate and correct from its peak levels. The Artemis Medicare share price has shown a 1-month return of approximately -2.13% and a 3-month return of -15.0% as of April 2026, indicating recent consolidation.

The Artemis Medicare price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 28.2% year-on-year growth in net profit for Q1 FY26, the Artemis Medicare price showed a positive reaction. The Artemis Medicare price has shown a pattern of strong positive momentum in periods when the company’s bed capacity expansion announcements exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Artemis Medicare stock price. Corporate developments, including strategic announcements such as the agreement to operate Vimhans Hospital, the IFC investment of Rs 330 crore for capacity expansion, and the company’s focus on high-margin specialties, have also influenced short-term fluctuations in the Artemis Medicare price. The Artemis Medicare share price has shown a 1-year return of approximately -19.96% as of April 2026, reflecting the correction from its 2023-24 highs. The Artemis Medicare share price has shown a 10-year aggregate net profit that reflects the company’s improving profitability over the long term. The Artemis Medicare share price reached its 52-week high of ₹306.00 before declining to its 52-week low of ₹203.35, reflecting the volatility inherent in the healthcare space. The Artemis Medicare share price has shown a year-to-date return that has been negative as of April 2026, indicating pressure in the current fiscal year. Comprehending these patterns in the Artemis Medicare share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Artemis Medicare stock price movements illustrate how industry fundamentals, regulatory policy cycles, and investor expectations converge in market pricing.

The Artemis Medicare share price has shown distinct seasonal patterns over the past decade. The best performing year historically was 2023 with a positive return, while the worst year was 2025 with a significant decline. In terms of annual performance, the Artemis Medicare share price delivered a 1-year return of -19.96%, a 3-year return of -3.45%, a 5-year return of 7.95%, and a 10-year return of 6.58%. The Artemis Medicare price has demonstrated that the stock tends to perform better in periods of strong healthcare demand and supportive government policies, while underperforming during phases of regulatory uncertainty and intense competition. The Artemis Medicare stock price has shown a 3-year total return of -3.45%, indicating the challenges faced in the healthcare sector in recent years. The Artemis Medicare stock price has shown a 5-year total return of 7.95%, reflecting the company’s ability to deliver positive returns across market cycles. The Artemis Medicare stock price continues to trade at a significant discount from its 52-week high of ₹306.00, standing at around ₹225-230 levels as of April 2026.

Artemis Medicare Services Limited Investor Relevance and Role in Portfolio

Artemis Medicare holds a significant position for portfolio investors who seek exposure to India’s healthcare sector with a focus on multi-specialty tertiary care hospitals. The company’s presence in high-growth specialties such as oncology, neurosciences, and cardiac care aligns it with investment strategies that value healthcare delivery, rising insurance penetration, and the medical tourism theme. The Artemis Medicare share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor bed occupancy rates, average revenue per occupied bed (ARPOB), and capacity expansion metrics when evaluating allocation decisions.

Institutional stakeholders play an increasingly significant role in Artemis Medicare’s ownership profile. As of December 2025, Promoters hold 58.39% of the company. Mutual funds hold 1.69% of the company. Key mutual fund holders include HSBC Asset Management (India) Private Limited – HSBC Mutual Fund – HSBC Focused Equity Fund, and Bandhan Mutual Fund – Bandhan Small Cap Fund. Foreign Institutional Investors (FIIs) hold a portion of the company, while Domestic Institutional Investors (DIIs) hold a portion. Institutional investors as a whole have increased holdings from 11.66% to 21.54% in the December 2025 quarter. Retail and other shareholders hold approximately 20% of the company. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

Based on data, the Artemis Medicare share price exhibits varying levels of beta and volatility across different measurement periods. Based on data, the long-term beta stands at approximately -0.05 according to Stockanalysis, while the Economic Times Tamil reports a beta of 1.00, reflecting different measurement periods and methodologies. Based on data, the daily-one month beta shows low correlation, while the daily-three month beta indicates moderate sensitivity. Based on data, the weekly-one year beta shows varying correlation levels. Based on data, the weekly-two year beta shows low correlation, and the 2 week-two year range beta is also low. Based on data, the monthly-two year beta continues to show moderate correlation. Supporting statistics include mean values across different periods and standard deviations indicating moderate variability. The weekly volatility stands at approximately 3.71%, which is stable compared to the broader market. Overall, the Artemis Medicare stock price demonstrates a moderate volatility profile with beta values suggesting the stock tends to move with varying sensitivity to broader market direction over different time frames.

The Artemis Medicare share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Artemis Medicare stock price’s beta reflects that the company’s established hospital operations and accredited facilities may provide some stability, though the healthcare sector remains sensitive to regulatory changes and economic cycles.

Artemis Medicare Services Limited Sectoral Relevance and Peer Positioning

The sector relevance of Artemis Medicare is anchored in its role within the broader Indian hospital and healthcare services industry, where it competes with other multi-specialty hospital chains. As part of this industry, the company’s strategic positioning connects multi-specialty tertiary care services to patients across India and international medical tourists. Competitors in the hospital and healthcare services segment include companies such as Apollo Hospitals Enterprise Limited, Max Healthcare Institute Limited, Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Aster DM Healthcare Limited, Global Health Limited, and Krishna Institute of Medical Sciences Limited. Firms with parallels in either bed capacity or specialty mix are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Artemis Medicare P/E ratio have shown variations over different periods. The current P/E ratio stands at approximately 42.16 across different sources, while the industry P/E stands at approximately 88. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. The Artemis Medicare P/E ratio has fluctuated with the company’s earnings growth trajectory.

Similarly, Artemis Medicare EPS has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and new service introductions supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from regulatory changes and competitive pressures have moderated EPS momentum. Artemis Medicare earnings have shown a trajectory that responded to both volume growth and margin pressures over the analysed period. The diluted EPS has shown consistent growth, with TTM EPS of ₹6.07 as per various sources. According to historical data, Adj EPS was ₹6.07 in 2025, ₹5.27 in 2024, ₹4.33 in 2023, ₹3.48 in 2022, and ₹2.66 in 2021, showing consistent growth over the past five years.

Artemis Medicare market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving healthcare market. Over years, the Artemis Medicare market cap has followed a pattern of significant growth followed by moderation. The market cap increased from approximately ₹3,483-3,683 crore as of April 2026. This growth mirrors the trend in the Artemis Medicare share price and the broader performance of the healthcare sector relative to broader market indices.

Artemis Medicare earnings over the past several years have been characterised by a period of consistent growth. Total revenue increased from ₹408.40 crore in FY2021 to ₹554.80 crore in FY2022, ₹737.43 crore in FY2023, ₹878.57 crore in FY2024, and ₹936.92 crore in FY2025, representing a 5-year CAGR of approximately 18-20%. Profit After Tax increased from ₹6.49 crore in FY2021 to ₹31.81 crore in FY2022, ₹38.60 crore in FY2023, ₹49.14 crore in FY2024, and ₹82.63 crore in FY2025, showing strong growth momentum. For the trailing twelve months (TTM) as of April 2026, revenue stood at ₹913.26 crore with net profit of ₹83.46 crore. For the quarter ended December 2025, net sales were ₹272.35 crore, up 17.2% year-on-year, with net profit of ₹22.34 crore, up 8.09% year-on-year.

Artemis Medicare EPS has shown variation over the past decade. The diluted EPS stood at ₹6.07 (TTM) as of April 2026, with the TTM P/E ratio at 42.16. The EPS growth rate has shown significant variation, with the company delivering a growth rate of 49.54% in FY2025 and 18.89% in FY2024. According to historical data, EPS was ₹6.07 in 2025, ₹5.27 in 2024, ₹4.33 in 2023, ₹3.48 in 2022, and ₹2.66 in 2021.

The Artemis Medicare P/E ratio has shown fluctuations over the available period. At the end of recent fiscal years, the P/E ratio varied, with current levels at 42.16x across different sources, while the industry P/E stands at approximately 88x. The mean historical P/E ratio over the last five years has been in the range of 30-50x. The current P/E ratio compared to the historical average reflects that investor expectations are adjusting to near-term earnings momentum. The Artemis Medicare share price has been influenced by these valuation metrics. The Artemis Medicare stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Artemis Medicare Services Limited is a leading multi-specialty hospital chain listed on both the NSE and BSE, where the Artemis Medicare share price reflects healthcare demand trends, bed capacity expansion, and specialty mix within the hospital sector. Its representation on stock exchanges supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare industry themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s hospital services market.